Alembic Limited (ALEMBICLTD) AI Stock Analysis

• Market Cap: ₹18.21B
• Dividend Yield: 2.36%
• Average Volume (3M): 22.23K
• Price to Earnings (P/E): 10.8
• Beta (1Y): 1.51
• Revenue Growth: 16.53%
• EPS Growth: 4.37%
• Country: IN
• Employees: 285
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.34
• Shares Outstanding: 256,781,830
• 10 Day Avg. Volume: 15,327
• 30 Day Avg. Volume: 22,227
• PEG Ratio: 0.53
• Price to Book (P/B): 1.10
• Price to Sales (P/S): 11.55
• P/FCF Ratio: 71.97
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: ₹79.00 ▼(-23.60% Downside)
• Action: Upgraded Date: 10/24/25
• Date: Action: Upgraded 10/24/25

Alembic Limited's strong financial performance and attractive valuation are the primary drivers of its stock score. The company's robust revenue growth and profitability metrics, combined with a low P/E ratio and reasonable dividend yield, suggest a solid investment opportunity. However, mixed technical indicators and potential sustainability concerns regarding profit metrics slightly temper the overall outlook.

Positive Factors

Low leverage / strong capital structure

Extremely low leverage and a 93.4% equity ratio give durable financial flexibility. This reduces refinancing and solvency risk, supports steady R&D/capex funding or distributions, and lets management withstand industry cyclicality without requiring immediate deleveraging.

Negative Factors

Unusually high reported net margin

A 140% net margin is inconsistent with operational norms and suggests one-offs or accounting items are inflating earnings. This undermines the reliability of reported profitability, complicates forecasting and makes underlying recurring earnings and return expectations uncertain.

Alembic Limited Business Overview & Revenue Model

Company Description

Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). It operates through API and Real Estate segments. The company is also involved in the construction of resident...

Read more

Alembic Limited engages in the manufacturing and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). It operates through API and Real Estate segments. The company is also involved in the construction of resident...

How the Company Makes Money

Alembic Limited makes money primarily by selling pharmaceutical products, with revenue generated from (1) finished dosage formulations (FDFs) and (2) active pharmaceutical ingredients (APIs). In its India business, it earns revenue from branded fo...

Read more

Alembic Limited makes money primarily by selling pharmaceutical products, with revenue generated from (1) finished dosage formulations (FDFs) and (2) active pharmaceutical ingredients (APIs). In its India business, it earns revenue from branded fo...

Alembic Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.24B	2.22B	1.57B	1.18B	713.69M	678.37M
Gross Profit	1.58B	1.53B	872.46M	702.07M	404.50M	392.74M
EBITDA	1.72B	1.69B	1.12B	939.86M	1.03B	213.43M
Net Income	3.24B	3.11B	2.69B	1.91B	2.22B	3.43B
Balance Sheet
Total Assets	27.27B	25.03B	23.29B	22.05B	26.32B	24.09B
Cash, Cash Equivalents and Short-Term Investments	888.10M	582.80M	129.05M	464.09M	270.77M	225.14M
Total Debt	125.80M	144.50M	91.49M	0.00	0.00	2.77M
Total Liabilities	1.91B	1.64B	1.43B	1.27B	1.35B	1.12B
Stockholders Equity	25.36B	23.39B	21.86B	20.78B	24.97B	22.97B
Cash Flow
Free Cash Flow	257.50M	356.00M	-336.03M	130.35M	-535.60M	-496.37M
Operating Cash Flow	489.60M	863.70M	226.87M	388.52M	-177.47M	-21.82M
Investing Cash Flow	135.10M	-265.80M	258.36M	72.96M	188.48M	-348.69M
Financing Cash Flow	-639.70M	-583.40M	-481.94M	-463.88M	-58.16M	-153.62M

Alembic Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 103.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ALEMBICLTD, the sentiment is Negative. The current price of 103.4 is above the 20-day moving average (MA) of 81.95, above the 50-day MA of 89.59, and above the 200-day MA of 101.31, indicating a bearish trend. The MACD of -4.65 indicates Positive momentum. The RSI at 26.71 is Positive, neither overbought nor oversold. The STOCH value of 19.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ALEMBICLTD.

Alembic Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	79 Outperform	₹756.90B	18.87	―	0.33%	7.33%	-3.79%
ALEMBICLTD	74 Outperform	₹18.21B	10.80	―	2.36%	16.53%	4.37%
IPCALAB	73 Outperform	₹406.62B	27.58	―	0.28%	9.66%	25.79%
ALKEM	72 Outperform	₹634.09B	25.97	―	0.80%	9.32%	11.25%
APLLTD	57 Neutral	₹130.10B	31.27	―	1.28%	11.42%	-1.91%
GLENMARK	53 Neutral	₹602.02B	35.61	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%